

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

TAKEDA PHARMACEUTICALS
U.S.A., INC.,

Plaintiff,

V.

MYLAN PHARMACEUTICALS INC.,

Defendant.

C.A. No. 19-2216-RGA

**PLAINTIFF'S AMENDED NOTICE OF APPEAL TO THE
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT**

An amended Notice of Appeal is hereby given under Fed. R. App. 3 that Plaintiff Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) hereby appeals to the United States Court of Appeals for the Federal Circuit from: (1) the January 27, 2020 Memorandum Order (D.I. 114) denying Takeda’s motion for a preliminary injunction; and (2) all other adverse opinions, orders, decisions, rulings, and findings underlying the Court’s denial of Takeda’s motion for a preliminary injunction. On January 27, 2020, Takeda filed its original Notice of Appeal (D.I. 115). Then on January 28, 2020, the Court corrected a typographical error and replaced the pdf of its January 27, 2020 Memorandum Order (D.I. 114) with a corrected version. Out of an abundance of caution, we are now filing an amended Notice of Appeal.

January 28, 2020

Respectfully Submitted by

/s/ Francis DiGiovanni

Francis DiGiovanni (No. 3189)
Thatcher A. Rahmeier (No. 5222)
DRINKER BIDDLE & REATH LLP
222 Delaware Avenue, Suite 1410
Wilmington, DE 19801
(302) 467-4200
francis.digiovanni@dbr.com
thatcher.rahmeier@dbr.com

Of Counsel:

Edgar H. Haug
Porter F. Fleming
Nicholas F. Giove
HAUG PARTNERS LLP
745 Fifth Avenue, 10th Floor
New York, NY 10151
(212) 588-0800
ehaug@haugpartners.com
pfleming@haugpartners.com
ngiove@haugpartners.com

Attorneys for Plaintiff